anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sleep disturbances associates closely with chronic pain. It now seems that sleep problems usually precede and maintain persistent pain. Anxiety and worry frequently precede and associate with disturbed sleep and chronic pain. Depression is usually a consequence of chronic pain. Pain and depression disturb sleep further. These elements form a vicious circle where poor sleep is a critical driver.

Previous studies have shown that sleep disturbances are a major contributor to the poor health-related quality of life (HRQoL) of patients with chronic pain.
Those in the intermittent unpredictable condition will be eligible to receive a contingency management voucher on one day a week. Participants in this group will receive a voucher for $22.00 following their first 3 methamphetamine-negative urine tests. They will then be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. They will receive a voucher for $35.50 for the provision of their second set of 3 consecutive instances of methamphetamine-negative urine samples, $49.00 for their third set of 3 consecutive instances, and so forth. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test. All participants will provide observed urine samples M, W, \& F for 12 wks and complete measures 1x/wk.
Subjects will receive a single oral dose of Camizestrant on Day 1 of treatment period 1. Following washout period of 7 to 10 days, subjects will receive Itraconazole on Days 1, 2, and 3 of treatment period 2, and single oral dose of Camizestrant plus a dose of Itraconazole on Day 1, followed by Itraconazole alone on Day 2 and Day 3 of treatment period 3.
Patient is to take Pico Salax oral bowel preparation which is a combination product consisting of 10 mg picosulfate sodium, 3.5 g magnesium oxide, and 12 g citric acid per sachet the day prior to surgery. Patient is to take 2 doses of this product, as per standard packaging instructions from the manufacturer. Specifically patient is to take the first packet contents dissolved in 150 mL water at 3pm the day before surgery. Patient is to take the second packet dissolved in 150 mL water at 8pm the day before surgery. Patient should drink 2-3L of clear liquids after each dose, for a total of 4-6L.
This study aimed to assess the efficacy of Nitraria retusa extract (NRE) in reducing weight, body mass index (BMI), body fat composition (BF), and anthropometric parameters among overweight/obese women, comparing the results with those of a placebo group. Overweight/obese individuals participated in a 12-week, double-blind, randomized, placebo-controlled trial. Body weight, BMI, body composition, and anthropometric parameters were assessed. Additionally, lipid profile and safety evaluation parameters were evaluated. Compared to the placebo group, the NRE group exhibited a mean weight loss difference of 2.27 kg (p < 0.001) at the trial's conclusion. Interestingly, the most significant weight reduction, amounting to 3.34 kg ± 0.93, was observed in younger participants with a BMI > 30.0. Similarly, BMI and BF% significantly decreased in the NRE group, contrary to the placebo group (p = 0.008 and p = 0.005, respectively). The percentage of body water (BW) (p = 0.006) as well as the ratio of LBM/BF (p = 0.039) showed a significant increase after the NRE intervention compared to the placebo. After age adjustment, all variables, except LBM/BF, retained statistical significance. Additionally, all anthropometric parameters were significantly reduced only in the NRE group. Most importantly, a significant reduction in Triglyceride (TG) levels in the NRE group was revealed, in contrast to the placebo group (p = 0.011), and the significance was still observed after age adjustment (p = 0.016). No side effects or adverse changes in kidney and liver function tests were observed in both groups. In conclusion, NRE demonstrated potent antiobesity effects, suggesting that NRE supplementation may represent an effective alternative for treating obesity compared to antiobesity synthetic drugs.
The invention belongs to the technical field of medicines, and particularly relates to a myocardial small molecular compound for idiosyncratically promoting proliferation of myocardial cells and application thereof. The myocardial small molecular compound total comprises a type A, a type B and a type C which have a common core structure, namely (3 (1, 2, 4) triazole (3, 4-b) (1, 3, 4) bismuththiol). The myocardial small molecular compound is obtained from a small molecular compound library by means of model organism zebra fish screening, so as to be capable of idiosyncratically promoting proliferation of myocardial cells inside zebra fish bodies. Importantly, the myocardial small molecular compound is capable of inducing embryonic stem cells of a small mouse to differentiate and proliferate towards the myocardial cells. As proved, the myocardial small molecular compounds are antagonists to inhibit wnt signaling pathways. The myocardial small molecular compound can be used as pilot drugs for treating heart diseases and further is used for optimizing and evaluating candidate drug targets thereof.
Inhaled colistimethate sodium twice daily. The active pharmaceutical ingredient consisting of pure CMS one million international units (MIU) / 80 mg of CMS / 33 mg colistin base activity (CBA) was provided as a powder for nebuliser solution in 10R International Organization for Standardization (ISO) glass vials.
Participants in the intervention group will undergo, in addition to the standard of care, 6+/-1 weeks of a personalized multimodal prehabilitation program. The interventions included will be patient-centered, aiming to optimize patients' preoperative health status while enhancing their empowerment and engagement.
Temozolomide pills are to be taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule. Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
Participants with severe symptoms (PHQ-9: 15-27; GAD-7: 15-21) will be randomized to high intensity stepped care (consist of a CBT workbook with accompanying psychotherapy by a Master's-level therapist delivered by telephone) or EUC. EUC consist of information about referrals/resources locally and nationally.
The invention mainly relates to the technical field of alcohol processing, and discloses a settling treatment method of yellow wine. The method comprises the following steps: settling egg white, settling traditional Chinese medicines, refrigerating and settling, stabilizing the settling, and packaging the finished product. The method is simple, and prolongs the settling time of yellow wine to 6 years, so that the mouthfeel of the yellow wine prepared by the method has similar mouthfeel to the yellow wine aged for 1 year; and the settling time is shortened to 25-30 days, so that the cost is lower, and the economic income is enhanced by 18.3%. The egg white powder is added into the yellow wine, uniformly mixed under the ultrasonic action and stood at normal temperature, thereby enriching the nutrient substances in the yellow wine, accelerating the precipitation of excess tannin matters and enhancing the stability of the yellow wine. The traditional Chinese medicine extract is added into the yellow wine after egg white settling to increase the nutrient and health-care components in the yellow wine, so that the yellow wine has softer mouthfeel and sweet aftertaste, enhances the immunity, and reduces the injuries of alcohol to the human body. After being refrigerated, the yellow wine has thick mouthfeel and higher stability. The edible alkali solution is added into the yellow wine, thereby highlighting the yellow wine fragrance, keeping the yellow wine clear and transparent, and prolonging the shelf life of the yellow wine.
Patients' medical records are reviewed retrospectively and prospectively. Patients are followed up by email, telephone, or U.S. mail every 4 months for up to 10 years from date of initial study enrollment. Patients, who are beyond 5 years from their initial diagnosis, are followed up by email, telephone, or U.S. mail annually.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies including cerliponase alfa.

In Trials 1 and 2 [see Clinical Studies (14)], 19 of 24 (79%) and 10 of 24 (42%) patients treated with BRINEURA developed anti-drug antibodies (ADAs) in serum and CSF, respectively. Drug-specific neutralizing antibodies (NAb) capable of inhibiting receptor-mediated cellular uptake of cerliponase alfa were detected in the CSF of 3 of 24 (13%) patients at a single visit and were undetectable in all other CSF samples tested in ADA positive patients. In Trial 3 [see Clinical Studies (14)], 14 of 14 (100%) and 3 of 14 (21%, all of the 3 patients were < 3 years of age) patients treated with BRINEURA developed ADAs in serum and CSF, respectively. NAb responses were not detected in the CSF of any ADA positive patients. Overall, patients younger than 3 years of age had higher ADA titers compared to patients 3 years of age and older.

In Trials 1 and 2, patients who experienced moderate to severe hypersensitivity adverse reactions were tested for drug-specific IgE and found to be negative. No association was found between serum ADA titers and incidence or severity of hypersensitivity. In Trial 3, hypersensitivity occurred in higher percentage in BRINEURA-treated patients < 3 years of age at baseline (amongst these patients, one patient experienced anaphylaxis), and higher ADA titers were also observed in this age group compared to patients ≥ 3 years of age at baseline. There was no identified clinically significant effect of ADA on pharmacokinetics or efficacy of BRINEURA. There is insufficient information to characterize the effects of ADA on safety.
<P>PROBLEM TO BE SOLVED: To provide an emulsifying method for preparing pharmaceutical preparations of multivesicular liposomes having characteristics of sustained release, and to provide pharmaceutical preparations produced by using the method.  <P>SOLUTION: Multivesicular liposomes are prepared at commercial scales by combining a first w/o emulsion with a second aqueous solution to form a w/o/w emulsion using a static mixer. Solvent is removed from the resulting emulsion to form multivesicular liposome-containing compositions. Further optional process steps include primary filtration and secondary cross-flow filtration. The produced products can be produced through a series of aseptic steps.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.
JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips at Day 1. Participants were eligible to receive optional touch-up retreatment one month following initial treatment if applicable.
<P>PROBLEM TO BE SOLVED: To provide an electronic medical record system that enables a terminal device connected via a wide area network such as the Internet to interactively image-process image data associated with an electronic medical record and observe the image-processed image.  <P>SOLUTION: A high speed data processing device is installed near the network of a PACS server for saving medical image data. An electronic medical record creation device attaches information and image processing parameters about image data used at an image diagnosis to an electronic medical record. The electronic medical record browsing terminal device uses the information attached to the electronic medical record to send the information for image data acquisition and the image processing parameters to the data processing device near the PACS server saving the image data. The data processing device acquires and image-processes the image data according to the information and parameters, and sends the created image to the terminal device. Related information is likewise acquired and displayed. The terminal device can thus interactively process and display the image and information associated with the electronic medical record.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Statistical artificial intelligence for advanced deep learning and probabilistic programming in the biosciences is provided. In various embodiments, biological data of a population is read. The biological data include molecular features of the population. A plurality of features of the population is extracted from the biological data. The plurality of features is provided to a first trained classifier to determine a subset of the plurality of features distinguishing the population. A plurality of genes associated with the subset of the plurality of features is determined. The plurality of genes is provided to a second trained classifier to determine a subset of the plurality of genes distinguishing the population. A dependence model is applied to the subset of the plurality of genes to determine one or more drug target.
PURPOSE:To obtain the subject compound of high safety, having excellent antineoplastic activity, useful as e.g. a carcinostatic agent, consisting of a cyclic hexapeptide compound having a specific amino acid sequence obtained by chemical modification of the extract from Rubia cordifolia L., a kind of medicinal herb. CONSTITUTION:RA-VII extracted from Rubia cordifolia L., a kind of medicinal herb, is dissolved in dichloromethane followed by adding an aqueous 50% NaOH solution, 3-bromopropene and tetra-n-butylammonium bromide to the resultant solution and then vigorously agitating the solution at room temperature. After a lapse of 5 hours, 3-bromobenzene and tetra-butylammonium bromide are further added to the solution followed by vigorous agitation at room temperature for 18hr. The resultant reaction liquor is then diluted with dichloromethane and then washed with water, 1N HCl and then saturated saline solution, and the resultant organic layer is dried with magnesium sulfate, filtered and then concentrated at reduced pressures, and the resultant concentrate is purified by silica gel column chromatography, thus obtaining the objective cyclic hexapeptide of the formula [R is formula R<1>CH2 (R<1> is 1-10C alkyl, aryl, etc.); X is O or S; Me is methyl].
Disclosed herein is a wax-based emulsion for the treatment of dry eye conditions by reducing the evaporation rate of saline and increasing the viscosity of the tear film. The composition of the present invention comprises an emulsion of wax dispersed in saline. One embodiment of the wax-based emulsion of the present invention comprises a wax in an amount ranging from about 0.001% to about 80% by weight and the remainder saline. In another embodiment, the wax-based emulsion further comprises a hydrocarbon in an amount ranging from about 0.01% to about 80% by weight. In still another embodiment, the wax-based emulsion of the present invention further comprises a cholesterol ester ranging in an amount from about 0.01% to about 80% by weight. In an alternative embodiment, the wax-based emulsion of the present invention further comprises an opthalmic drug in an amount ranging from about 0.01% to about 80% by weight. In yet another embodiment, the wax based emulsion comprises a wax in an amount ranging from about 40% to about 60% by weight, a cholesterol ester in an amount ranging from about 10% to about 20% by weight and the remainder saline. The wax based emulsion may further comprise a hydrocarbon in an amount of up to about 20% by weight. In yet another embodiment, the emulsion further comprises an amount ranging between about 1% to about 20% by weight of standard opthalmic drugs such as antibiotics for delivery to the eye. In some embodiments, the wax of the emulsion is a synthetic wax.
Total hip arthroplasty (THA) is a surgery that relieves hip joint pain and improves its functions and is widely performed in the elderly population. New analgesic methods need to be developed to protect these patients from the pain and side effects of opioids used for treatment. Many scales are available to indicate postoperative patient recovery. One of these is the quality of recovery-15 (QoR-15) recovery test, which was first applied by Stark et al. in 2013. The investigators think that an ESPB applied from the sacral region will spread to the lumbar region by diffusion, affect the lumbar plexus, and provide complete analgesia in the ventral and dorsal regions of the hip by affecting the sacral plexus in the sacral region. The investigator's primary aim in this study is to evaluate the effect of sacral erector spinae plane block (S-ESPB) on the quality of recovery and healing after TKA, through the QoR-15 score, and to evaluate its effect on postoperative pain.

Anesthesia Technique and Analgesia Protocol a standard to measure postoperative pain severity after THA, and intravenous injection is used as a standard in patients with no contraindications within the scope of the multimodal analgesia protocol. paracetamol 1 gr. 3x1 + Dexketoprofen 50 mg 2x1 and when NRS is 3 and above, 1mg/kg tramadol is administered as a rescue analgesic. In addition, ESPB is applied to patients as a part of multimodal analgesia after THA surgery, unless there are contraindications in the hospitals where the study will be conducted. And 4 mg IV is routinely administered to patients with postoperative nausea and vomiting. Ondansetron is administered . All patients will receive routine monitoring and routine anesthesia management. 20 gauge to patients Intravenous ( IV ) cannulation is provided and 15ml/kg/ h Isotonic fluid will be started. The spinal anesthesia will be applied to the patients by administering 3cc of 0.5% bupivacaine through the L3-L4 or L4-L5 intervertebral space. Patients will then be released to the surgical team for THA surgery. After the surgical procedure is completed, patients will be transferred to the postanesthetic care unit (PACU) for observation. S-ESPB will be applied to patients in Group S
Intervention B is based on speed, COD and plyometrics (i.e., a "potentiation" protocol), inspired by ideas presented by Howe, Coward, and Price (2017). Participants will perform five repetitions of the following exercises, in this order: unilateral hurdle hops and lateral hurdle hops with each lower limb; CMJ; broad jump; forward in and out; slalom jumps; lateral scissor jumps; single leg linear hops. Each intervention will last \~10 minutes and will be applied in the football field.
AIMS: Atrial fibrillation (AF) is a common arrhythmia, and many cases of AF may be undiagnosed. Whether screening for AF and subsequent treatment if AF is detected can improve long-term outcome remains an unsettled question. The primary aim of the NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial is to assess whether self-screening for AF with continuous electrocardiogram (ECG) for 3-7 days in individuals aged 65 years or older with at least one additional risk factor for stroke, and initiation of guideline-recommended therapy in patients with detected AF, will reduce the occurrence of stroke.
METHODS AND RESULTS: This study is a nationwide open, siteless, randomized, controlled trial. Individuals ≥65 years of age are randomly identified from the National Population Register of Norway and are invited to take a digital inclusion/exclusion test. Individuals passing the inclusion/exclusion test are randomized to either the intervention group or the control group. A total of 35 000 participants will be enrolled. In the intervention group, self-screening is performed continuously over 3-7 days at home with a patch ECG device (ECG247) at inclusion and after 12-18 months. If AF is detected, guideline-recommended therapy will be initiated. Patients will be followed up for 5 years through national health registries. The primary outcome is time to a first stroke (ischaemic or haemorrhagic stroke). The first participant in the NORSCREEN trial was enrolled on 1 September 2023.
CONCLUSION: The results from the NORSCREEN trial will provide new insights regarding the efficacy of digital siteless self-screening for AF with respect to stroke prevention in individuals at an increased risk of stroke.
TRIAL REGISTRATION: Clinical trials: NCT05914883.
In this group, adolescents with anxiety disorders will be recruited. It was planned to include 30 participants. Additionally, the specification of which anxiety disorders are assigned to the participants will also be provided. Escitalopram treatment will be given to participants with anxiety disorders with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
Disclosed are new, useful and non-obvious methodologies and compositions of matter for the treatment of chronic traumatic encephalopathy (CTE) using stem cells and cells possessing stem cell-like activity. The treatment of CTE is accomplished by utilizing stem cells to: a) reduce oxidative stress; b) suppress inflammation; c) enhance neurogenesis; and d) stimulate axonal regrowth. In one embodiment said stem cells are mesenchymal stem cells derived from umbilical cord and other perinatal tissues. In another embodiment, said stem cells are bone marrow derived. In yet another embodiment said stem cells are adipose derived. In one embodiment, products derived from said regenerative cells are comprised of cellular lysate, apoptotic bodies, exosomes, and other microvesicles. In one embodiment, said regenerative cells and/or said products derived from said regenerative cells are administered subsequent to one ore multiple head injuries. In other embodiments said products are administered in combination with neurorestorative and/or neuroprotective interventions.